Avelas Welcomes Susan Stimson to its Board of Directors
November 22, 2019
SAN DIEGO, November 22, 2019 – Avelas Biosciences, Inc., a clinical-stage oncology company developing AVB-620 for real-time cancer detection is pleased to announced the addition of Susan Stimson as a Director of the company.
“Susan brings an exceptional background and skillset to the Avelas Board. She has had incredible success throughout her career and her knowledge and experiences will be very valuable in guiding Avelas towards a successful commercialization of AVB-620,” said Jay Lichter, Chairman, President and Chief Executive Officer of Avelas.
With over 20 years’ experience in healthcare, Susan is recognized as a respected leader in development and commercialization of new medical technologies. She currently serves as Executive in Residence on KCK Group’s Medical Technology team, where she applies her expertise to their portfolio of commercial stage medtech companies and evaluates new investment opportunities.
She previously served as Chief Strategy Officer of Intersect ENT, a publicly traded medical device company. As part of the founding team of Intersect ENT, Susan played an instrumental role in the company’s evolution from R&D stage to high growth commercial business by building and leading a variety of its commercial and strategic functions including Marketing, Market Access, International Sales, Business Development and Customer Service and also led the company’s transformation from medical device to pharmaceutical business as General Manager.
Prior to that, Ms. Stimson served as an executive of start-up company Mitralign, designing and executing the company’s marketing, clinical, and regulatory strategies. Her experience stems from many years at Guidant Corporation responsible for top priority products from the aspects of R&D, marketing, and sales. Ms. Stimson holds a B.S. in Biomedical Engineering from Marquette University, Milwaukee, Wisconsin.
About Avelas Biosciences
Avelas Biosciences is a San Diego-based drug-device company focused on developing AVB-620, a novel drug-device combination product for use during cancer surgery. AVB-620 improves surgery by detecting cancer in real-time and has the potential to become part of standard-of-care treatment for a variety of cancer surgeries. AVB-620 has completed a Phase Ib clinical trial assessing safety, pharmacokinetics, and fluorescence properties using tissue image analysis. A Phase II clinical trial for AVB-620 in breast cancer is ongoing. Avelas was founded on technology from Roger Y. Tsien, Ph.D., co-winner of the 2008 Nobel Prize in chemistry.